Journal of Gynecologic Oncology

Korean Society of Gynecologic Oncology (대한부인종양학회)
권호 표지
DOI QR코드

DOI QR Code

Plasma levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in women with cervical neoplasia

  • Lee, Si-Won (Department of Obstetrics and Gynecology, Cheil General Hospital and Women's Healthcare Center, Kwandong University College of Medicine) ;
  • Lee, Soo-Yoon (Department of Obstetrics and Gynecology, Medical Research Institute, Ewha Womans University School of Medicine) ;
  • Lee, Sa-Ra (Department of Obstetrics and Gynecology, Medical Research Institute, Ewha Womans University School of Medicine) ;
  • Ju, Woong (Department of Obstetrics and Gynecology, Medical Research Institute, Ewha Womans University School of Medicine) ;
  • Kim, Seung-Cheol (Department of Obstetrics and Gynecology, Medical Research Institute, Ewha Womans University School of Medicine)
  • Received : 2009.12.03
  • Accepted : 2010.08.05
  • Published : 2010.09.20
⟨ Previous Next ⟩

Abstract

Objective: The goal of this study was to investigate the relationship between plasma levels of insulin-like growth factors-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) and the risk for cervical intraepithelial neoplasia (CIN) and cervical cancer. Methods: Plasma levels of IGF-1 and IGFBP-3 of 44 cervical cancer patients, 82 CIN patients and 40 neoplasm-free patients were investigated. Then the associations of the plasma levels of IGF-1 and IGFBP-3 with cervical neoplasm or its clinicopathologic parameters were analyzed. Results: The mean IGF-1 concentrations were significantly different among the control, CIN, and cervical cancer groups; the levels were higher in the CIN group compared to the controls. According to the quartile category, the plasma IGF-1 level was significantly higher (p=0.0015) in the CIN group than in the controls. The IGFBP-3 level showed no association between the controls and CIN groups (p=0.842). Although the mean IGF-1/IGFBP-3 molar ratio had borderline significance (p=0.08) among the study population, the quartile comparison showed a significantly higher IGF-1/IGFBP-3 molar ratio in the CIN group compared to the control group (p=0.041). Conclusion: Plasma levels of IGF-1 and the IGF-1/IGFBP-3 molar ratio might be useful for the development early detection of cervical lesions and used as an adjuvant diagnostic tool for cervical neoplasia after more larger scale research.

Keywords

References

  1. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res 1990; 50: 7415-21.
  2. Kim K, Ryu SY. Major clinical research advances in gynecologic cancer 2009. J Gynecol Oncol 2009; 20: 203-9. https://doi.org/10.3802/jgo.2009.20.4.203
  3. Sara VR, Hall K. Insulin-like growth factors and their binding proteins. Physiol Rev 1990; 70: 591-614. https://doi.org/10.1152/physrev.1990.70.3.591
  4. Rosenfeld RG, Lamson G, Pham H, Oh Y, Conover C, De Leon DD, et al. Insulinlike growth factor-binding proteins. Recent Prog Horm Res 1990; 46: 99-159.
  5. Baxter RC, Saunders H. Radioimmunoassay of insulin-like growth factor-binding protein-6 in human serum and other body fluids. J Endocrinol 1992; 134: 133-9. https://doi.org/10.1677/joe.0.1340133
  6. Furlanetto RW, Harwell SE, Frick KK. Insulin-like growth factor-I induces cyclin-D1 expression in MG63 human osteosarcoma cells in vitro. Mol Endocrinol 1994; 8: 510-7. https://doi.org/10.1210/me.8.4.510
  7. Minshall C, Arkins S, Straza J, Conners J, Dantzer R, Freund GG, et al. IL-4 and insulin-like growth factor-I inhibit the decline in Bcl-2 and promote the survival of IL-3-deprived myeloid progenitors. J Immunol 1997; 159: 1225-32.
  8. LeRoith D, Werner H, Beitner-Johnson D, Roberts CT Jr. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995; 16: 143-63. https://doi.org/10.1210/edrv-16-2-143
  9. Stewart CE, Rotwein P. Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev 1996; 76: 1005-26. https://doi.org/10.1152/physrev.1996.76.4.1005
  10. Esposito DL, Blakesley VA, Koval AP, Scrimgeour AG, LeRoith D. Tyrosine residues in the C-terminal domain of the insulin-like growth factor-I receptor mediate mitogenic and tumorigenic signals. Endocrinology 1997; 138: 2979-88. https://doi.org/10.1210/en.138.7.2979
  11. Hongo A, D'Ambrosio C, Miura M, Morrione A, Baserga R. Mutational analysis of the mitogenic and transforming activities of the insulin-like growth factor I receptor. Oncogene 1996; 12: 1231-8.
  12. LeRoith D, Baserga R, Helman L, Roberts CT Jr. Insulin-like growth factors and cancer. Ann Intern Med 1995; 122: 54-9. https://doi.org/10.7326/0003-4819-122-1-199501010-00009
  13. Hakam A, Yeatman TJ, Lu L, Mora L, Marcet G, Nicosia SV, et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 1999; 30: 1128-33. https://doi.org/10.1016/S0046-8177(99)90027-8
  14. Xie Y, Skytting B, Nilsson G, Brodin B, Larsson O. Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype. Cancer Res 1999; 59: 3588-91.
  15. Ferry RJ Jr, Katz LE, Grimberg A, Cohen P, Weinzimer SA. Cellular actions of insulin-like growth factor binding proteins. Horm Metab Res 1999; 31: 192-202. https://doi.org/10.1055/s-2007-978719
  16. Arany E, Afford S, Strain AJ, Winwood PJ, Arthur MJ, Hill DJ. Differential cellular synthesis of insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-3 within human liver. J Clin Endocrinol Metab 1994; 79: 1871-6. https://doi.org/10.1210/jc.79.6.1871
  17. Ballard FJ, Knowles SE, Walton PE, Edson K, Owens PC, Mohler MA, et al. Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I), IGF-II and des (1-3) IGF-I in rats. J Endocrinol 1991; 128: 197-204.
  18. Pollak M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer 2000; 36: 1224-8. https://doi.org/10.1016/S0959-8049(00)00102-7
  19. Giovannucci E. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr 2001; 131(Suppl 11): 3109S-20S. https://doi.org/10.1093/jn/131.11.3109S
  20. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472-89. https://doi.org/10.1093/jnci/92.18.1472
  21. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst 2002; 94: 972-80. https://doi.org/10.1093/jnci/94.13.972
  22. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563-6. https://doi.org/10.1126/science.279.5350.563
  23. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, et al. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998; 90: 911-5. https://doi.org/10.1093/jnci/90.12.911
  24. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999; 91: 151-6. https://doi.org/10.1093/jnci/91.2.151
  25. Steller MA, Delgado CH, Zou Z. Insulin-like growth factor II mediates epidermal growth factor-induced mitogenesis in cervical cancer cells. Proc Natl Acad Sci U S A 1995; 92: 11970-4. https://doi.org/10.1073/pnas.92.26.11970
  26. Wu X, Tortolero-Luna G, Zhao H, Phatak D, Spitz MR, Follen M. Serum levels of insulin-like growth factor I and risk of squamous intraepithelial lesions of the cervix. Clin Cancer Res 2003; 9: 3356-61.
  27. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 1978; 253: 2769-76.
  28. Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer 1992; 65: 311-20. https://doi.org/10.1038/bjc.1992.65
  29. Rogler CE, Yang D, Rossetti L, Donohoe J, Alt E, Chang CJ, et al. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem 1994; 269: 13779-84.
  30. Steller MA, Delgado CH, Bartels CJ, Woodworth CD, Zou Z. Overexpression of the insulin-like growth factor-1 receptor and autocrine stimulation in human cervical cancer cells. Cancer Res 1996; 56: 1761-5.
  31. Serrano ML, Romero A, Cendales R, Sanchez-Gomez M, Bravo MM. Serum levels of insulin-like growth factor-I and -II and insulin-like growth factor binding protein 3 in women with squamous intraepithelial lesions and cervical cancer. Biomedica 2006; 26: 258-68. https://doi.org/10.7705/biomedica.v26i2.1415
  32. Bustin SA, Jenkins PJ. The growth hormone-insulin-like growth factor-I axis and colorectal cancer. Trends Mol Med 2001; 7: 447-54. https://doi.org/10.1016/S1471-4914(01)02104-9
  33. Gomez JM, Mourot B, Fostier A, Le Gac F. Growth hormone receptors in ovary and liver during gametogenesis in female rainbow trout (Oncorhynchus mykiss). J Reprod Fertil 1999; 115: 275-85. https://doi.org/10.1530/jrf.0.1150275
  34. Mathur RS, Mathur SP. In vitro downregulation of growth factors by insulin-like growth factor binding protein-3 in cervical cancer. Gynecol Oncol 2003; 91: 410-5. https://doi.org/10.1016/S0090-8258(03)00513-4
  35. Conover CA, Powell DR. Insulin-like growth factor (IGF)-binding protein-3 blocks IGF-I-induced receptor down-regulation and cell desensitization in cultured bovine fibroblasts. Endocrinology 1991; 129: 710-6. https://doi.org/10.1210/endo-129-2-710
  36. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-9. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
  37. Dassonville O, Formento JL, Francoual M, Ramaioli A, Santini J, Schneider M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993; 11: 1873-8. https://doi.org/10.1200/JCO.1993.11.10.1873
  38. Nakamura K, Hongo A, Kodama J, Miyagi Y, Yoshinouchi M, Kudo T. Down-regulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines. Cancer Res 2000; 60: 760-5.
  39. Berger AJ, Baege A, Guillemette T, Deeds J, Meyer R, Disbrow G, et al. Insulin-like growth factor-binding protein 3 expression increases during immortalization of cervical keratinocytes by human papillomavirus type 16 E6 and E7 proteins. Am J Pathol 2002; 161: 603-10. https://doi.org/10.1016/S0002-9440(10)64215-0

Cited by

  1. Obesity and excess protein and carbohydrate consumption are risk factors for thyroid cancer. vol.64, pp.8, 2012, https://doi.org/10.1080/01635581.2012.721154
  2. Molecular and Circulatory Expression of Insulin Growth Factors in Indian Females with Advanced Cervical Cancer vol.13, pp.12, 2010, https://doi.org/10.7314/apjcp.2012.13.12.6475
  3. Targeting IGF-1 signaling pathways in gynecologic malignancies vol.17, pp.3, 2010, https://doi.org/10.1517/14728222.2013.749863
  4. Analysis of cytosine-adenine repeats in P1 promoter region of IGF-1 gene in peripheral blood cells and cervical tissue samples of females with cervical intraepithelial lesions and squamous cervical ca vol.11, pp.2, 2010, https://doi.org/10.3892/mmr.2014.2916
  5. The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in Asia vol.20, pp.9, 2010, https://doi.org/10.1634/theoncologist.2015-0111
  6. Effects of Long-Term Mineral Block Supplementation on Antioxidants, Immunity, and Health of Tibetan Sheep vol.172, pp.2, 2010, https://doi.org/10.1007/s12011-015-0593-z
  7. Linking type 2 diabetes and gynecological cancer: an introductory overview vol.56, pp.9, 2010, https://doi.org/10.1515/cclm-2017-0982
  8. Multivariate Analysis on the Effects of Diabetes and related Clinical Parameters on Cervical Cancer Survival Probability vol.9, pp.None, 2010, https://doi.org/10.1038/s41598-018-37694-1
  9. A patient with solid gynecologic cancer causing lactic acidosis, severe hypercalcemia, and hypoglycemia vol.7, pp.1, 2010, https://doi.org/10.1002/ccr3.1904
  10. IGFBP-2 in cervical cancer development vol.113, pp.None, 2020, https://doi.org/10.1016/j.yexmp.2019.104362
  11. Associations of Dietary Glycemic Index, Glycemic Load and Carbohydrate with the Risk of Cervical Intraepithelial Neoplasia and Cervical Cancer: A Case-Control Study vol.12, pp.12, 2020, https://doi.org/10.3390/nu12123742
  12. miR-186-3p attenuates the tumorigenesis of cervical cancer via targeting insulin-like growth factor 1 to suppress PI3K-Akt signaling pathway vol.12, pp.1, 2010, https://doi.org/10.1080/21655979.2021.1977053
  13. Blood‐based biomarkers of human papillomavirus–associated cancers: A systematic review and meta‐analysis vol.127, pp.6, 2010, https://doi.org/10.1002/cncr.33221
  14. Gut Microbiota and Gynecological Cancers: A Summary of Pathogenetic Mechanisms and Future Directions vol.7, pp.5, 2010, https://doi.org/10.1021/acsinfecdis.0c00839